NeurosciencebioRxivPreprint
Gene Editing for ATXN3 Inactivation in Machado-Joseph disease: CRISPR-Cas9 as a Therapeutic Alternative to TALEN-Induced Toxicity
Sara Monteiro Lopes, Miguel Monteiro Lopes, Daniela Camargo de Oliveira…·Luís Pereira de Almeida
This study compares CRISPR-Cas9 and TALEN gene editing in a mouse model of Machado-Joseph disease, showing CRISPR-Cas9 reduces ATXN3 aggregates and delays disease progression.
DOI 10.1101/2025.02.14.637261